Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof
A hyposialylated rhEPO formulation with a tailored isoelectric point and glycosylation profile, produced via fermentation and chromatography, addresses the limitations of existing rhEPO by enhancing neuroprotection and neurorepair while minimizing hematopoietic effects, effectively treating neurological disorders.
Patent Information
- Application Number
- JP2024151043
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-09-05
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing recombinant human erythropoietin (rhEPO) formulations exhibit adverse events due to hematopoietic activity and have short plasma half-lives, limiting their neuroprotective efficacy in clinical applications, despite promising non-clinical studies.
A pharmaceutical composition of hyposialylated rhEPO with a specific isoelectric point profile (4.25-5.85) and unique glycosylation pattern is produced through a fermentation and chromatography process using a Q quaternary ammonium ligand anion exchanger, without chemical or genetic modifications, enhancing neuroprotective and neurorepair mechanisms.
The composition demonstrates higher efficacy in neuroprotection and neurorepair both in vitro and in vivo, effectively treating neurological disorders such as dementia, stroke, and Parkinson's disease, with improved stability and reduced hematopoietic effects.
Smart Images

Figure 2024164273000010 
Figure 2024164273000011 
Figure 2024164273000012
Abstract
Description
[Technical field]
[0001] Scope of technology The present invention relates to the fields of biotechnology and medicine, and in particular to obtaining pharmaceutical compositions of recombinant human erythropoietin having a glycosylation pattern that confers properties that allow its use in disorders of the nervous system.
[0002] background Erythropoietin (EPO) is a glycoprotein hormone formed by 166 amino acids with a molecular weight of 30.4 kDa (Lanfranco, F and Strasburger, CJ (2016) Sports Endocrinology 47: 115-27). EPO is naturally produced in the perisinusoidal cells of the liver during fetal and perinatal life, and in adulthood mainly in the interstitial fibroblasts of the kidney. This hormone stimulates the production of red blood cells in the bone marrow and plays an important role in the brain's response to neuronal injury (Siren L. et al. (2001) Proc Natl Acad Sci USA 98 (7): 4044-9).
[0003] EPO is a highly glycosylated molecule, the carbohydrate moiety of which constitutes 40% of its molecular weight. The protein contains four complex chains of oligosaccharides linked to the polypeptide chain, three of which are N-linked and one O-linked, the locations of which have been well described by different authors Elliott, S. et al. (2004) The Journal of Biological Chemistry, 279(16): 16854-16862; Watson et al. (1994) Glycobiology 4(2): 227-237. Oligosaccharides with N-linkages can contain a variable number of sialic acid terminal residues and are important for secretion, molecular stability, receptor binding and in vivo activity (Egrie, J. and Browne, J. (2001) Br. J. Cancer, 84(1):3-10; Goldwasser et al. (1974) J. Biol. Chem 249:4202-4206).
[0004] From the 1990s to the present, a great deal of evidence has been accumulated regarding the neuroprotective properties of recombinant human EPO (rhEPO). In 1998, Sakanara and colleagues demonstrated that in a global ischemia model in gerbils, delivery of rhEPO through the lateral ventricle after occlusion of the common carotid artery resulted in reduced ischemic damage to hippocampal neurons in the CA1 region (Sakanara, M. et al. (1998) Proc. Natl. Acad. Sci. USA, 95:4635-4640).
[0005] The cytoprotective effect of EPO on the central nervous system was demonstrated in 2004 by Maiese and colleagues, and then in 2005 by Viviani and colleagues (Maiese, K. et al. (2004) Trends in Pharmacological Sciences 25(11):577-83; Viviani, D. et al. (2005) Journal of Neurochemistry 93(2):257-268). Despite all the information accumulated in non-clinical studies on hematopoietic EPO, the results obtained have not been reproduced in the clinic due to adverse events occurring in patients with its long-term use.
[0006] In adults, expression of EPO receptors in the nervous system is found primarily in neurons, astrocytes, and microglia, although astrocytes produce EPO as hyposialylated EPO (Nagai, A. et al. (2001) Journal of Neuropathology & Experimental Neurology, 60(4):317-319).
[0007] A number of researchers have taken up the task of modifying rhEPO in order to obtain drugs with the same neuroprotective properties but without the adverse events caused by its hematopoietic effects. The EPO obtained by total enzymatic desialylation of rhEPO, called AsialoEPO (US2004 / 0122216), has the desired properties mentioned above, and this type of EPO has high affinity for rhEPO receptor, but its plasma half-life is very short, limiting its protective effect. Another example of modification of erythropoietin is the conversion of lysine to homocitrulline by carbamylation of the protein, resulting in carbamylated EPO, called CEPO (Leist, M., Ghezzi, P., Grasso, G. et al. (2004) 305 (5681): 239-242). Both EPOs did not show hematopoietic effects, but clinical trials conducted with CEPO did not demonstrate neuroprotective efficacy, even though no adverse effects were observed.
[0008] Patent application WO2007 / 009404 claims a different intranasal formulation of EPO with low sialic acid content, later called NeuroEPO in the authors' publication (Garcia, JC and Sosa, I. (2009), The Scientific World Journal, 9:970-981). This rhEPO is obtained by a hollow fiber membrane fermentation process and ion exchange chromatography in the purification to separate the most acidic isoforms (high sialic acid content from low sialic acid content). The NeuroEPO has a profile of 13 isoforms, 9 of which are shared with the hematopoietic rhEPO called EPOCIM®.
[0009] The inventors of the present invention describe for the first time a stirred tank (ST) production process combined with a purification step performed by chromatography using a monolithic column as an anion exchanger with a quaternary ammonium ligand Q that allows for increased expression of rhEPO hyposialylated isoforms without additional chemical and genetic modifications. These isoforms have an isoelectric point profile in the pH range of 4.25-5.85 and a different glycosylation-related tertiary structure from NeuroEPO that results in higher efficacy in neuroprotective and neurorepair mechanisms both in vitro and in vivo.
[0010] Brief description of the invention In one aspect, the object of the present invention is a pharmaceutical composition comprising as an active ingredient rhEPO having an isoform profile with an isoelectric point in the range of 4.25 to 5.85, which has microheterogeneity of fucosylated N-glycans formed by bi-, tri- and tetra-antennary structures with mono- and bi-sialylated sialic acid residues representing 40-60%, tri- and tetra-sialylated sialic acid residues representing 40-43% and tetra-sialylated sialic acid residues representing 10-13% of the total glycans, and a pharma- ceutically acceptable excipient.
[0011] In particular, the O-glycosylation site at serine 126 has three sialo-types with 0–2 sialic acid residues, with the monosialylated structure being the most abundant, representing 78–82% of all glycans, whereas the non-sialylated structure represents 6–10% of all glycans.
[0012] The N-glycosylation site at asparagine 83 is - Fucosylated biantennary structures with one and two sialic acid residues, which structures represent 8 to 12% of all glycans; - Fucosylated triantennary structures with 1, 2 and 3 sialic acid residues, which structures represent 17-21% of all glycans; - Fucosylated tetraantennary structures having 1 to 4 sialic acid residues, which structures represent 27 to 31% of all glycans, and - Fucosylated tetraantennary structures with N-acetyllactosamine type 1 and 2 having 1 to 4 sialic acid residues, these structures representing 38 to 42% of all glycans; Includes.
[0013] Pharmaceutically acceptable excipients for the pharmaceutical compositions claimed in the present invention include, but are not limited to, bioadhesive polymers, such as hydroxypropyl methylcellulose, and protein stabilizers, such as L-tryptophan, L-leucine, L-arginine hydrochloride, and L-histidine hydrochloride.
[0014] The above structure of the rhEPO isoforms that are part of the pharmaceutical compositions of interest in the present invention renders the compositions more effective in neuroprotective and neurorepair mechanisms both in vitro and in vivo.
[0015] In another aspect, the object of the present invention is a method for obtaining unmodified rhEPO, the fermentation process is carried out in perfusion mode in ST at a temperature range of 34±2° C., with a protein-free culture medium in the pH range of 7.2-7.3, which is supplemented with glutamine until a final concentration of 8-12 mmol / L is obtained. The method also includes a purification process having a chromatography step, in which a monolithic column is used as an anion exchanger with Q quaternary ammonium ligand, the equilibration buffer is a 20 mmol / L Tris 10 mmol / L HCl solution with a pH range of 7.9-8.10 and a conductivity range of 1.35-1.65 mS / cm, and the purification process uses a 50 mmol / L sodium acetate elution buffer with a pH of 4.3-4.5 and a conductivity of 2-3.5 mS / cm.
[0016] In the methods of the present application, the pharmaceutical compositions contain an increased number of low sialic acid content isoforms that have a different glycosylation-related tertiary structure from NeuroEPO, which results in greater efficacy in neuroprotective and neurorepair mechanisms both in vitro and in vivo.
[0017] The use of the pharmaceutical compositions described herein for treating dementia, stroke, Parkinson's disease, ataxia, craniocerebral trauma, glaucoma, autism, neonatal hypoxia, multiple sclerosis, amyotrophic lateral sclerosis, and trauma-, toxicosis- or radiation-induced neurological damage is also an object of the present invention. In particular, methods are described for treating subjects in need of such treatment using such pharmaceutical compositions, the administration of which is in the range of 0.1 mg to 4 mg in a volume of 1 mL, 1 to 3 times per week for a period of 6 to 12 months. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Pharmaceutical Compositions The object of the rhEPO of the present invention is characterized by having an isoelectric point profile of 4.25-5.85 and secondary and tertiary protein structures not associated with glycosylation similar to rhEPO, which retains the same tertiary structure associated with glycosylation, with an O-glycosylation site at serine 126 and three N-glycosylation sites at asparagines 24, 38 and 83. The carbohydrate composition of the rhEPO described herein distinguishes it from other rhEPOs. The microheterogeneity of the fucosylated N-glycans is composed of bi-, tri- and tetra-antennary structures with mono- and bi-sialylated sialic acid residues in the range of 40-60% of the total carbohydrate, preferably in the range of 43-50%, tri-sialylated sialic acid residues in the range of 40-43% and tetra-sialylated sialic acid residues in the range of 10-13% of the total carbohydrate.
[0019] In particular, the O-glycosylation site at serine 126 has three sialo forms with 0–2 sialic acid residues, with the monosialylated structure being the most abundant, representing 78–82% of the total glycans, and the non-sialylated structure representing 6–10% of the total glycans.
[0020] The N-glycosylation site at asparagine 83 is - Fucosylated biantennary structures having one and two sialic acid residues, which structures represent 8 to 12% of all glycans; - Fucosylated triantennary structures with 1, 2 and 3 sialic acid residues, which structures represent 17-21% of all glycans; - Fucosylated tetraantennary structures having 1 to 4 sialic acid residues, which structures represent 27 to 31% of all glycans; - Fucosylated tetraantennary structures with N-acetyllactosamine type 1 and 2 having 1 to 4 sialic acid residues, these structures being in the range of 38 to 42% of the total glycans; Includes.
[0021] The terms hyposialylated rhEPO, EPO, HS or basic isoform are used interchangeably in the present invention to refer to a pharmaceutical composition having the above characteristics, also commonly referred to as NeuroEPO plus.
[0022] The pharmaceutical composition of interest of the present invention has hyposialylated isoforms of rhEPO as active ingredients.These hyposialylated isoforms are obtained by the process described in the present invention, which does not imply chemical and / or genetic modification of rhEPO to obtain said isoforms.The rhEPO isoforms that are part of the active ingredients of the pharmaceutical composition have a different tertiary structure associated with glycosylation than NeuroEPO, which results in higher efficacy in neuroprotective and neurorepair mechanisms both in vitro and in vivo.
[0023] The pharmaceutical compositions of interest of the present invention are in the form of an aqueous solution administered by nasal or ocular routes of administration, the final dosage form of which is nasal drops, nasal spray or eye drops. The pharmaceutical formulations contain hyposialylated rhEPO as an active ingredient and, optionally, pharma- ceutical suitable excipients and / or stabilizers.
[0024] Pharmaceutically acceptable excipients and / or stabilizers are non-toxic to subjects administered at the dosages and concentrations employed, and may include bioadhesive polymers such as hydroxymethylcellulose, hydroxypropylcellulose, and methylcellulose, and protein stabilizers such as L-tryptophan, L-leucine, L-arginine hydrochloride, and / or L-histidine hydrochloride, and salts thereof.
[0025] Treatment Uses and Methods The present invention provides a pharmaceutical composition useful for treating nervous system disorders such as cerebrovascular disease, psychiatric disease and neurodegenerative disease. In particular, the disease may be dementia, stroke, Parkinson's disease, ataxia, craniocerebral trauma, glaucoma, autism, neonatal hypoxia, multiple sclerosis, amyotrophic lateral sclerosis, and trauma, toxicosis or radiation induced neurological damage.
[0026] The invention further provides a method comprising administering hyposialylated rhEPO to a subject in need of such treatment, 1-3 times per week for a period of 6-12 months. The administration is performed intranasally (IN) gradually by instillation of the drug into mucose. The administered dose ranges from 0.1 mg to 4 mg, preferably 0.5 mg to 1 mg. The maximum administered volume per dose is 1 mL, 0.5 mL per nostril for a total daily dose of 3 mL. The volume can be dispensed in smaller volumes with a time interval of 5-15 minutes between each application, preferably every 15 minutes.
[0027] Methods for obtaining hyposialylated isoforms of rhEPO The method claimed in this invention consists of different steps and uses the cell lines described below.
[0028] cell line The cell lines that can be used to carry out the method object of the present invention are the same as those reported for the production of rhEPO. The most used lines are CHO, COS, BHK, Namalwa, HeLa, Hep3B, HepG2, and the CHO cell line is preferably used in the present invention.
[0029] Fermentation Process The fermentation process of the invention is carried out using ST technology. Such a process consists of several stages, the first of which involves thawing an ampoule from the working cell bank until it reaches room temperature (18-24°C). This is followed by a multiplication stage in which the cells are adjusted to a cell concentration and cell viability that ensures proper inoculation of the seed fermenter with the aim of increasing the biomass.
[0030] 1×10 6 Once a cell density of 1000 cells / mL or more has been reached, the fermentation is started with different operating modes. These modes can be batch cultures, continuous cultures with or without biomass retention.
[0031] To obtain the hyposialylated isoform, a temperature in the range of 34±2° C. and a pH in the range of 6.8±0.4 should be ensured at this stage of the fermentation.
[0032] Cells should be grown in protein-free culture medium until a final concentration of glutamine in the range of 8-12 mmol / L is obtained.
[0033] Refining Process The purification process for hyposialylated rhEPO involves the following chromatographic steps.
[0034] First, pseudo-affinity chromatography with a colored ligand is performed. The purpose of this step is to capture rhEPO and partially remove the main contaminants present in the supernatant (SN). Then, gel filtration chromatography is performed to change the protein buffer to the buffer of the application solution for the next chromatography step.
[0035] Then, a pseudo affinity chromatography using metal chelate is performed. This step aims to capture rhEPO and completely remove the fraction of contaminants that were not removed in the previous step of the process. Gel filtration chromatography is performed again, and the buffer is changed to the buffer of the application solution of the next chromatography step.
[0036] An important stage of the process involves anion exchange chromatography using Q quaternary ammonium ligand. A monolithic column is used for this chromatography step. The objectives of this chromatography are separation of the hyposialylated (biologically active) isoform from the acidic isoform, retention of DNA and concentration of the product. All of this ensures that the hyposialylated isoform is obtained without contamination or mixing with the acidic isoform.
[0037] Finally, the buffer is changed and gel filtration chromatography is performed again with the aim of eluting the protein in active crude form. [Brief description of the drawings]
[0038] [Figure 1] Isoform profiles: A) Isoform cleavage definition; B) SN produced in cultures under the evaluated temperature and pH conditions. [Diagram 2] FIG. 1 shows the percentage of hyposialylated isoforms in cultures under the temperature and pH conditions evaluated. [Diagram 3] FIG. 1 shows the percentage of hyposialylated isoforms in each culture under the conditions evaluated at pilot scale. [Figure 4] FIG. 13. Relative intensities of less acidic isoforms in SN. [Diagram 5] FIG. 1 shows the effect of mobile phase pH and conductivity on the static adsorption capacity of Q quaternary ammonium ligands of rhEPO isoforms: (A) hyposialylated (basic), (B) acidic. [Figure 6] Breakthrough curves A): Chromatography matrix "Q SFF", B): Monolithic column "CIM QA". [Figure 7] FIG. 13 shows the effect of elution buffer pH on the performance of basic and acidic isoforms. [Figure 8]FIG. 1 shows the distribution of hyposialylated isoforms of rhEPO at production scale. [Figure 9] FIG. 1 shows the study of the N-glycans of hyposialylated rhEPO by zwitterionic hydrophilic interaction liquid chromatography coupled with mass spectrometry. [Figure 10] FIG. 1 shows extracted ion electropherograms (EIEs) of hyposialylated rhEPO O126 glycopeptide glycoforms observed upon digestion with a) trypsin and neuraminidase and b) trypsin. [Figure 11] FIG. 1 shows EIE of N83 glycopeptide in which glycoforms resulting from trypsin digestion and neuraminidase digestion are observed. [Figure 12] FIG. 1 shows the EIE of hyposialylated rhEPO N83 glycopeptide in which glycoforms resulting from digestion with a) trypsin and neuraminidase and b) trypsin are observed. [Figure 13] FIG. 1 shows cell viability profiles of astrocyte cultures 24 and 48 hours after cell injury with 8% dimethylsulfoxide (DMSO) and subsequent treatment with hyposialylated rhEPO. [Figure 14] Kaplan-Meier chart showing the 7-day survival rate. [Figure 15] FIG. 1 shows the neurological status of animals 24 hours after infarction. [Figure 16] FIG. 1 shows the effect of application of different rhEPO isoforms on reticulocyte numbers in a normocytic mouse model.
[0039] The present invention will be further described with the aid of the following examples and figures, which are not, however, intended to be construed as limiting the scope of the invention.
[0040] example Example 1. Effect of pH and temperature on laboratory-scale rhEPO isoform profile. A seed cell bank was generated from a CHO cell line transfected with the human EPO gene that was adapted to grow in suspension in protein-free medium, with complete adaptation to this culture medium being obtained after 37 generations, corresponding to a culture period of 25 days.
[0041] To evaluate the performance of the cell lines in the presence of different pH and temperature conditions, an experimental design combining both variables was performed. The experimental conditions are shown in Table 1. The pH of the culture was controlled by adding 0.5 mol / L sodium hydroxide. [Table 1]
[0042] The isoform profile of rhEPO corresponding to the samples of SN produced in the cultures of the different conditions evaluated was determined by isoelectric focusing. A mixture of ampholines with pH ranges of 2-5 and 3-10 was used, and an internal EPOCIM® reference material was used as a control. The intensity percentage of each isoform in the samples was analyzed by densitometry using the Gene Tools program. Isoforms with pH values ranging from 2.80 to 4.25 were defined as acidic isoforms, and isoforms with pH values ranging from 4.25 to 6.55 were defined as basic isoforms (Figure 1A).
[0043] Figure 1B shows that the isoform profile was strongly affected by temperature. Regardless of pH, seven acid isoforms were observed when SN samples corresponding to each condition were compared to the control at a temperature of 37° C. Meanwhile, at 35° C., a decrease in acid isoforms was observed, which was more pronounced at pH 7.2 and 7.3.
[0044] FIG. 2 shows that under conditions of pH 7.2 and 7.3 and a temperature of 35° C., the total amount of isoforms obtained (100%) was the basic isoform.
[0045] Example 2. Effect of pH and temperature on pilot-scale rhEPO isoform profile. For the best culture conditions obtained on laboratory scale (temperature 35° C., pH 7.2 and 7.3), the influence of a more controlled favorable environment for cell cultivation was evaluated. From the seed cell bank described in Example 1, four fermentation runs were planned using a ST-type bioreactor (Infors-AGCH4103, Bottmingen) with a working volume of 3.5 L. The operating conditions are shown in Table 2. The initial cell viability was above 90% in all conditions evaluated. [Table 2]
[0046] At the end of each fermentation, samples were taken and the isoform profiles of the SN samples produced in the cultures for the conditions evaluated in the bioreactor were determined by isoelectric focusing techniques. Once these profiles were obtained, the Gene Tools program was used to determine the intensity of each band present in the gel, starting from the image corresponding to the isoelectric focusing gel, and to estimate the proportion of hyposialylated isoforms for each condition.
[0047] As shown in FIG. 3, for culture conditions 2 and 3 (35° C., pH 7.2-7.3), the percentage of hyposialylated isoforms was higher than for conditions 1 and 4. These results confirm the findings obtained at laboratory scale, namely, that by modifying the operating conditions of pH 7.2-7.3 and temperature of 35° C., the isoform profile of rhEPO was also modified, resulting in greater intensity at pH values of 4.25-5 and 85.
[0048] Example 3. Increasing glutamine concentration in the culture medium promotes expression of rhEPO basic isoform. To assess whether increasing the glutamine concentration of the culture medium affected the increase in the hyposialylated isoform, the performance of a CHO cell line producing rhEPO was evaluated. A seed cell bank exposed to culture medium with different glutamine concentrations was used and acclimation to the culture medium was allowed for 15 days. The evaluation was carried out using a rolling bottle kept in a 37°C incubator with an agitation speed of 600 rpm, with 0.5 × 10 cells in a final volume of 300 mL culture medium.6 Initial cell concentrations were started at 100 cells / mL. The final glutamine concentrations of the culture medium were 8, 12 and 16 mmol / L, with culture medium containing 6 mmol / L glutamine used as a control.
[0049] The relative intensities of hyposialylated isoforms in the SN of cultures were assessed by densitometry after treatment with different concentrations of glutamine for 7 days.
[0050] Figure 4 shows that a higher percentage of hyposialylated isoforms was obtained for each of the three mutants evaluated compared to the control, confirming that increasing the glutamine concentration in the culture medium promotes the acquisition of hyposialylated isoforms of SN. The highest values for these isoforms were observed at 8 mmol / L glutamine (87%).
[0051] Example 4. Effect of pH and conductivity on the adsorption of acidic and basic isoforms of Q strong quaternary ammonium anion exchanger on laboratory scale. With the aim of determining the pH and conductivity conditions favoring maximum adsorption of the acidic isoforms on the Q strong quaternary ammonium anion exchanger, the following buffers were evaluated: 20 mmol / L sodium phosphate (anhydrous dibasic and monobasic dihydrate) and 20 mmol / L Tris 10 mmol / L HCl. The buffers were tested at different pH and conductivity values, pH between 6 and 8 and conductivities between 1.5 and 5 mS / cm.
[0052] Maximal adsorption of the acidic isoform to the exchanger was observed at pH 6 and a conductivity of 1.50 mS / cm, whereas adsorption of the hyposialylated (basic) isoform was maximized at pH 8 and a conductivity of 1.50 mS / cm. The results are shown in Figure 5.
[0053] Example 5. Better performance of Q strong anion matrix using integrated column technology in terms of its ability to separate rhEPO isoforms versus using the conventional technique of chromatography gels at laboratory scale. The dynamic adsorption capacity (Q) of each technology under study was calculated using two breakthrough curves, using two of the linear flow rates recommended by the manufacturer of each technology: 100 cm / h and 600 cm / h for the chromatographic gel technology (Q SFF), and 156 cm / h and 624 cm / h for the integrated column (CIM QA). The equilibration solution used for the prior art experiments and the integrated column technology was Tris-HCL buffer at pH 8 and conductivity 1.5 mS / cm, according to the results obtained in Example 4.
[0054] The rhEPO samples were applied to the column and samples were taken at different times at the outlet from the column. The protein (C) concentration of each sample was determined spectrophotometrically. The known values of C in each sample were used to calculate the fraction of non-adsorbed protein C / C0. The loading, which is the mass of protein applied to the column per unit volume of gel given in mg rhEPO / mL Q matrix, was calculated at each time.
[0055] In Figure 6, the values of C / C0 vs. dynamic capacity are graphically represented in breakthrough curves that allow to know the Q of the gel per fraction of non-adsorbed protein C / C0=0.1 at a particular flow rate. Figure 6A shows the breakthrough curves obtained with the prior art of chromatography gels, the lowest flow rates being the ones with the highest dynamic capacity. Figure 6B shows that the monolithic column has very similar dynamic capacities at the two linear flow rates tested, and therefore can be operated at higher flow rates without experiencing variations in the dynamic capacity of the matrix.
[0056] Table 3 shows the Q values obtained for the different measurements. [Table 3]
[0057] Comparing the results of Q study carried out on packed bed strong anion exchanger and monolithic column technology, it is observed that both technologies have similar Q at the lowest linear velocity studied.However, at the highest linear velocity, monolithic column has 1.40 times higher dynamic adsorption capacity than that of the traditional chromatographic matrix evaluated.Therefore, it can be concluded that monolithic column allows for increasing the workflow of the process without affecting the capacity to process purified rhEPO mass.
[0058] Example 6. Decreasing pH enhances elution of hyposialylated rhEPO isoforms on a lab-scale monolithic column. Experimental tests were performed using Q SFF and CIM QA columns. The equilibration solution used for both techniques was Tris-HCl buffer with pH 8 and conductivity 1.5 mS / cm according to Example 4. The working linear velocity of the Q SFF column was 600 cm / h and that of the monolithic column was 624 cm / h. The product used in the experiments was obtained from a "Sephadex" G-25 molecular exclusion chromatography column after performing a buffer change to the equilibration solution described above. For the elution of basic isoforms, several runs were performed with the monolithic anion exchange column using 50 mmol / L Tween 20 sodium acetate buffer at 0.01% at pH values of 4.41, 4.81, 5.06, 5.20.
[0059] The recoveries obtained for elution of the hyposialylated (basic) and acidic isoforms in each run are shown in Figure 7. Analysis of these results confirmed that as the pH of the elution buffer for basic isoforms increased, its performance decreased, therefore a 50 mmol / L sodium acetate buffer at pH 4.41 was chosen for elution.
[0060] Example 7. Consistency of isoform separation and purity for a production scale process to obtain hyposialylated rhEPO. Fermentation runs were performed from the seed cell bank described in Example 1, with initial cell viability greater than 90%. The fermentation stage was carried out at a temperature of 35° C., with the medium pH maintained at 7.2-7.3, with protein-free culture medium supplemented to reach a final glutamine concentration of 8 mmol / L.
[0061] After four harvests were obtained, a purification step was carried out, in which an anion exchanger with Q quaternary ligand was used in a monolithic column in the key step: Tris-HCl solution with pH 8 and conductivity 1.5 mS / cm was used as the equilibration buffer, and 50 mmol / L sodium acetate buffer with pH 4.41 was used for elution.
[0062] The isoform profile of the four batches of active material obtained after the purification process was determined by isoelectric focusing technique. A mixture of ampholines with pH ranges 2-5 and 3-10 was used, and an internal EPOCIM® reference material was used as control. Figure 8 shows the consistency of the separation of the isoforms, where an isoform profile composed by six major isoforms was observed, of which only two are shared with the control.
[0063] Furthermore, the sialic acid content of the purified isoforms was determined according to the procedure for measuring this molecule and the purity by reversed-phase HPLC described in Europe 8.0 Pharmacopoeia (2014). The obtained sialic acid content and purity results are shown in Table 4. [Table 4]
[0064] The sialic acid content was less than 10 moles of sialic acid per protein molecule and the purity was greater than 95% for the four batches. From these, it can be concluded that the process for obtaining hyposialylated rhEPO guarantees obtaining isoforms in the pH range of 4.25-5.85, which is different from the one observed for NeuroEPO.
[0065] Example 8. Tertiary structure of hyposialylated rhEPO exhibits characteristic microheterogeneity associated with glycosylation. Glycan analysis To study its N-glycan profile, hyposialylated rhEPO was subjected to a process of denaturation and enzymatic digestion with peptide N-glycosidase F (PNGase F). After the N-glycans were released, they were purified by solid-phase extraction using HyperSep Hypercab SPE cartridges (Mancera-Arteu, M. et al. (2016) Anal. Chim. Acta 940: 92-103. Subsequently, derivatization was performed according to the procedure described by Gimenez et al. in 2015 (Gimenez, E et al. (2015) Anal. Chim. Acta, 866: 59-68).
[0066] Zwitterionic-hydrophilic interaction capillary liquid chromatography coupled to mass spectrometry was performed according to the methodology described by Mancera-Arteu, M. et al. (2016) Anal. Chim. Acta 940:92-103.
[0067] Figure 9 shows the mass spectrum of the three glycans detected in hyposialylated rhEPO. As can be seen, glycan 3Ant2SiA1Fuc is the most abundant, while glycan 4Ant4SiA1Fuc is found in lower amounts.
[0068] Table 5 shows the relative area percentages of glycans by structure. [Table 5]
[0069] Table 6 shows the detected glycans with their corresponding relative areas, monoisotopic experimental molecular weights (Mexp) and mass errors. As can be seen, there are a significant number of glycans with low sialylated structures. [Table 6]
[0070] As shown in Table 6, glycans with more sialylated structures (four sialic acid molecules) are found in lower proportions. Instead, structures with sialic acid molecules not found in other rhEPOs, such as 3Ant1SiA1Fuc, 4Ant1SiA1Fuc, 4Ant1LacNAc1SiA1Fuc, and 4Ant3LacNAc1SiA1Fuc, are detected. The glycan 4Ant3Sia1Fuc is abundant in hyposialylated rhEPO. Similarly, it can be seen that the proportion of relative area due to branching to the total glycans detected is different from other rhEPOs, with structures with one or two sialic acid residues representing more than 50% of the relative area due to branching.
[0071] Glycopeptide analysis O 126 and N 83 To detect all glucoforms present in the glycopeptides, rhEPO and rhEPO-CRS (pharmacopoeia reference products) were subjected to digestion with trypsin and neuraminidase (rhEPO HS-TN). All sialoforms of each glucoform detected from the trypsin digestion analysis (rhEPO HS-T) were studied. Samples were analyzed by mass spectrometry according to the procedure described by Gimenez, E. et al. (2011) Rapid Commun Mass Spectrom 25:2307-2316.
[0072] 10A and 10B show the O detected in the rhEPO HS-TN and HS-T digests. 126 The EIEs of the glycopeptide glycoforms are shown. In the first one, neuraminidase causes complete desialylation of the glycopeptide, resulting in all sialoforms becoming a single glycoform, thus resulting in O 126 A single peak is observed, corresponding to the / 0SiA glycoform peak. In contrast, when digested with trypsin alone, three sialo forms, bearing 0, 1 and 2 sialic acid molecules, are observed.
[0073] Table 7 shows the O detected with the corresponding relative area, monoisotopic experimental molecular weight (Mexp) and mass error. 126 Shows sialomorphism. [Table 7]
[0074] The results obtained show that the most abundant sialoform is the one containing one sialic acid molecule. The relative area percentages of both the non-sialylated isoform and the isoform with only one sialic acid are higher compared to those described for other rhEPOs. Differences are found with CRS rhEPO in the percentages of both sialoforms.
[0075] In the case of the N83 glycopeptide, analysis of the rhEPO HS-TN digest detected six peaks corresponding to six different glycoforms that did not contain sialic acid. The resulting EIE is shown in Figure 11 and the detected glycoforms are listed in Table 8. The results obtained show that N 83 At this site, a higher proportion of complex desialylated tetraantennary structures is present. [Table 8]
[0076] Figure 12A shows that there is no separation between the different tetraantennary structures of the rhEPO HS-TN digest. In contrast, when sialylated glycoforms of the rhEPO HS-T digest are analyzed, a clear separation between them is observed, with those with three sialic acid residues having greater intensity (Figure 12B). These results are consistent with findings from glycan studies.
[0077] Table 9 shows all sialo forms detected and the corresponding relative areas, monoisotopic experimental molecular weights (Mexp) and mass errors. [Table 9]
[0078] The results confirm that hyposialylated rhEPO is characterized by fewer sialylated structures (e.g., 2Ant1SiA1Fuc or 3Ant1SiA1Fuc) when the protein is digested with trypsin alone. When the relative area percentages of mono- and bisialylated structures are examined, the results show that they correspond to approximately 60%.
[0079] The tetraantennary structure of the N83 glycopeptide was found in the highest proportion compared to other glycoforms, and the one with two sialic acid residues was the one with the highest proportion.
[0080] Example 9. The restorative effect of hyposialylated rhEPO on DMSO-induced cytotoxicity in astrocytes. PG4 astrocyte cell line was cultured in glucose-rich Dulbecco's Modified Eagle Medium (DMEM) culture medium supplemented with 3.7 g / L NaHCO3 and 10% fetal bovine serum (FBS). Cells were incubated for 24 h at a temperature of 37 °C in an atmosphere of 5% CO2 / 95% air. After the specified times, SN was extracted and cells were subjected to injury induced with 8% DMSO and incubated again for 24 h. Then, SN was removed and 2% DMEM culture medium containing different concentrations of hyposialylated rhEPO (1.25, 2.5, 5 and 10 ng / mL) was added. At 24 and 48 h, Alamar Blue reagent was added and cells were then incubated for 6 h and readings were taken at 540 / 630 nm. All incubations were performed at a temperature of 37 °C in an atmosphere of 5% CO2 / 95% air.
[0081] In Figure 13 it can be seen how different concentrations of hyposialylated rhEPO, 1.25, 2.5, 5 and 10 ng / mL, allowed the cells to regain viability, with the best condition being 1.25 ng / mL hyposialylated rhEPO, demonstrating the recovery capacity of astrocytes.
[0082] Example 10. Better neuroprotective activity of hyposialylated rhEPO than NeuroEPO. Gerbils from Mongolia were used to develop a model of persistent unilateral ischemia according to the methodology described by Kahn K. in 1972 (Kahn K. (1972) Minneap 22:510-515). The animals were then randomly assigned to five experimental groups. Group 1: Vehicle 10 μL of vehicle Group 2: treated with 0.142 mg / kg hyposialylated rhEPO Group 3: treated with 0.0142 mg / kg hyposialylated rhEPO Group 4: Treated with 0.142 mg / kg NeuroEPO Group 5: Treated with 0.0142 mg / kg NeuroEPO
[0083] Each treatment was administered intranasally three times daily for four days. The animals were evaluated during the first four days of treatment followed by a three day recovery period.
[0084] The results show significantly higher survival rates in animals treated with hyposialylated rhEPO at doses of 0.142 and 0.0142 mg / kg compared to vehicle, whereas NeuroEPO significantly reduced mortality only at the 0.142 mg / kg dose, but not at 0.0142 mg / kg (FIG. 14).
[0085] Neurological evaluation showed a neuroprotective effect of hyposialylated rhEPO (NeuroEPO plus), which significantly reduced the values of neurological measures in animals treated with the used dose of NeuroEPO plus compared to the placebo group and the group treated with NeuroEPO, the same results obtained with hyposialylated rhEPO could only be achieved at the dose of 0.142 mg / kg (Figure 15) (Duncan statistical test, p>0.05 between same letters, p<0.05 between different letters).
[0086] Example 11. Hyposialylated rhEPO does not increase reticulocyte count in a normocytic mouse model. B6D2F1 female mice were randomly assigned to six experimental groups of six animals each and received single doses of treatment as follows: Group 1: rhEPO working reference material at 0.003 mg / mL in a volume of 200 μL via the subcutaneous route (SC). Group 2: 0.006 mg / mL hyposialylated rhEPO in a volume of 200 μL via the SC route. Group 3: 0.5 mg / mL hyposialylated rhEPO in a volume of 200 μL via the IN route. Group 4: 1 mg / mL hyposialylated rhEPO in a volume of 200 μL via the IN route. Group 5: 2 mg / mL hyposialylated rhEPO in a volume of 200 μL via the IN route. Group 6: control, 200 μL vehicle via SC route.
[0087] The reticulocyte count results are shown in FIG. 16. As can be seen, there were no significant differences between the control and hyposialylated rhEPO treated animals by both SC and IN. The reticulocyte counts of animals treated with rhEPO working reference material were significantly higher than those of control and hyposialylated rhEPO treated animals using both routes. (Duncan's test, p>0.05 between same letters; p<0.05 between different letters)
[0088] These results demonstrate that hyposialylated EPO does not increase reticulocyte counts even at the highest dose established for this study, indicating that hyposialylated EPO has no hematopoietic effect.
[0089] [Claim 1] A pharmaceutical composition comprising as an active ingredient recombinant human erythropoietin (rhEPO) having an isoelectric point profile between 4.25 and 5.85. [Claim 2] The pharmaceutical composition according to claim 1, characterized in that: the microheterogeneity of fucosylated N-glycans is formed by bi-, tri- and tetra-antennary structures, with mono- and bi-sialylated sialic acid residues in the range of 40-60% of the total glycans, tri-sialylated sialic acid residues in the range of 40-43% of the total glycans, and tetra-sialylated sialic acid residues in the range of 10-13% of the total glycans; and Pharmaceutically acceptable excipients. [Claim 3] 2. The pharmaceutical composition of claim 1, characterized in that the O-glycosylation site at serine 126 has three sialo forms with 0-2 sialic acid residues, the monosialylated structure being the most abundant and representing 78-82% of the total glycans, and the non-asialylated structure representing 6-10% of the total glycans. [Claim 4] The pharmaceutical composition according to claim 1, characterized in that the N-glycosylation site at asparagine 83 comprises: - fucosylated biantennary structures with one and two sialic acid residues, which structures represent 8-12% of all glycans; - fucosylated triantennary structures with 1, 2 and 3 sialic acid residues, which structures represent 17-21% of all glycans; - fucosylated tetraantennary structures with 1 to 4 sialic acid residues, said structures representing 27 to 31% of all glycans; and - Fucosylated tetraantennary structures with N-acetyllactosamine types 1 and 2 present between 1 to 4 sialic acid residues, said structures representing 38 to 42% of all glycans; . [Claim 5] 2. The pharmaceutical composition of claim 1, wherein the pharma- ceutically acceptable excipient comprises a bioadhesive polymer and a protein stabilizer. [Claim 6] The bioadhesive polymer -hydroxymethylcellulose, -hydroxypropyl cellulose, methylcellulose, and The pharmaceutical composition according to claim 5, characterized in that it is selected from the group comprising: [Claim 7] The protein stabilizer -L-tryptophan, -L-leucine, -L-arginine hydrochloride, and -L-histidine hydrochloride, The pharmaceutical composition according to claim 5, characterized in that it is selected from the group comprising: [Claim 8] A method for obtaining rhEPO without additional chemical and genetic modifications and an isoelectric point profile of 4.25 to 5.85, comprising: The fermentation process takes place in a stirred tank; and In the purification process, a chromatography step is used using a monolithic column as an anion exchanger having a Q quaternary ammonium ligand. A method comprising: [Claim 9] 9. The method according to claim 8, characterized in that the fermentation process of rhEPO is carried out in a stirred tank in a protein-free culture medium supplemented with glutamine at a temperature of 35° C. and a pH range of 7.2-7.3 to give a final concentration between 8 mmol / L and 12 mmol / L. [Claim 10] 9. The method according to claim 8, characterized in that in the purification process, a 20 mmol / L Tris 10 mmol / L HCl solution with a pH of 8 and a conductivity of 1.5 mS / cm is used as the equilibration buffer, and a 50 mmol / L sodium acetate solution with a pH of 4.41 is used as the elution buffer. [Claim 11] A pharmaceutical composition, the active ingredient of which is hyposialic acid-added rhEPO obtained by the method according to claims 8 to 10. [Claim 12] Use of the pharmaceutical composition according to any one of claims 1 to 7 and 11 for the treatment of dementia, stroke, Parkinson's disease, ataxia, craniocerebral trauma, glaucoma, autism, neonatal hypoxia, multiple sclerosis, amyotrophic lateral sclerosis, and neurological damage induced by trauma, poisoning or radiation. [Claim 13] A method for treating a subject in need of such treatment, comprising administering a pharmaceutical composition according to any one of claims 1 to 7 and claim 11 in a volume of 1 mL, in a dosage range of 0.1 mg to 4 mg, 1 to 3 times per week for 6 to 12 months.
Claims
1. A pharmaceutical composition comprising as an active ingredient recombinant human erythropoietin (rhEPO) having an isoelectric point profile between 4.25 and 5.85, the microheterogeneity of fucosylated N-glycans is formed by bi-, tri- and tetra-antennary structures, with mono- and bi-sialylated sialic acid residues in the range of 40-60% of the total glycans, tri-sialylated sialic acid residues in the range of 40-43% of the total glycans, and tetra-sialylated sialic acid residues in the range of 10-13% of the total glycans; and Pharmacologically acceptable excipients, A pharmaceutical composition comprising: wherein the rhEPO is produced by a fermentation process carried out in a stirred tank at a temperature of 35° C. and a pH range of 7.2 to 7.3; Purification process in which a chromatography step is used using a monolithic column as an anion exchanger having a Q quaternary ammonium ligand is obtained by
2. 2. The pharmaceutical composition according to claim 1, characterized in that the O-glycosylation site at serine 126 has three sialo forms with 0-2 sialic acid residues, the monosialylated structures being the most abundant and accounting for 78-82% of the total glycans, and the non-sialylated structures accounting for 6-10% of the total glycans.
3. The pharmaceutical composition according to claim 1, characterized in that the N-glycosylation site at asparagine 83 comprises: - fucosylated biantennary structures with one and two sialic acid residues, which structures account for 8-12% of all glycans; - fucosylated triantennary structures with 1, 2 and 3 sialic acid residues, which structures account for 17-21% of all glycans; - fucosylated tetraantennary structures with 1 to 4 sialic acid residues, said structures accounting for 27 to 31% of all glycans; and - Fucosylated tetraantennary structures with N-acetyllactosamine types 1 and 2 carrying 1 to 4 sialic acid residues, which structures account for 38-42% of all glycans.
4. 2. The pharmaceutical composition of claim 1, wherein the pharma- ceutically acceptable excipient comprises a bioadhesive polymer and a protein stabilizer.
5. The bioadhesive polymer - hydroxymethylcellulose, - hydroxypropyl cellulose, methylcellulose, and The pharmaceutical composition according to claim 4, characterized in that it is selected from the group consisting of:
6. The protein stabilizer - L-tryptophan, - L-leucine, -L-arginine hydrochloride, and -L-histidine hydrochloride, The pharmaceutical composition according to claim 4, characterized in that it is selected from the group consisting of:
7. 2. The pharmaceutical composition according to claim 1, characterized in that the fermentation process for obtaining rhEPO is carried out in a protein-free culture medium supplemented with glutamine to give a final concentration between 8 mmol / L and 12 mmol / L.
8. 2. The pharmaceutical composition according to claim 1, characterized in that in the purification process, a 20 mmol / L Tris 10 mmol / L HCl solution with a pH of 8 and a conductivity of 1.5 mS / cm is used as the equilibration buffer, and a 50 mmol / L sodium acetate solution with a pH of 4.41 is used as the elution buffer.
9. 7. The pharmaceutical composition according to any one of claims 1 to 6 for use in the treatment of dementia, stroke, Parkinson's disease, ataxia, craniocerebral trauma, glaucoma, autism, neonatal hypoxia, multiple sclerosis, amyotrophic lateral sclerosis and trauma-, poisoning- or radiation-induced neurological damage.
Citation Information
Patent Citations
RH-EPO nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system
EP1997483A1
[erisuropoechinisohuomu[erisuropoechinisohuomu]
JP1992502331A
Therapeutic use of recombinant erythropoietin with high activity and reduced side effects
JP2004506652A
Fc-erythropoietin fusion protein with improved pharmacokinetics
JP2008504008A
Erythropoietin and analogs for veterinary use
WO2018226747A1
